Hemi-retinal vein occlusion: Characterizing a rare retinal vasculopathy

被引:0
|
作者
Kadam, Yogita [1 ,2 ]
Thaku, Pratima [3 ]
Das, Anthony Vipin [1 ,2 ]
Narayanan, Raja [2 ,3 ]
Senthil, Sirisha [4 ]
Takkar, Brijesh [2 ,3 ,5 ]
机构
[1] LV Prasad Eye Inst, Dept EyeSmart EMR & AEye, Hyderabad, Telangana, India
[2] LV Prasad Eye Inst, Indian Hlth Outcomes Publ Hlth & Econ Res Ctr, Hyderabad, Telangana, India
[3] LV Prasad Eye Inst, Anant Bajaj Retina Inst, Hyderabad, Telangana, India
[4] LV Prasad Eye Inst, VST Ctr Glaucoma Care, Hyderabad, Telangana, India
[5] Anant Bajaj Retina Inst, Kallam Anji Reddy Campus,LV Prasad Marg, Hyderabad 500034, Telangana, India
基金
英国惠康基金;
关键词
Big data; hemi-retinal vein occlusion (HRVO); macular edema; neovascular glaucoma; MACULAR EDEMA SECONDARY; RISK-FACTORS; BRANCH; OUTCOMES; MANAGEMENT; EFFICACY; DISEASE; SAFETY; CARE;
D O I
10.4103/IJO.IJO_1712_23
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To characterize hemi-retinal vein occlusion (HRVO) in patients presenting to a multi-tier ophthalmology hospital network. Methods: This retrospective, hospital-based study analyzed 2,834,616 new patients between August 2010 and June 2021. Patients with a clinical diagnosis of HRVO in at least one eye were included as cases. Data were collected using an electronic medical record system. Data were compared to the findings noted in branch RVO (BRVO) and central RVO (CRVO) patients. Results: HRVO constituted 0.9% (n = 191) of all the retinal vein occlusions (RVOs), with the mean age being 60.55 +/- 10.14 years. Most patients were male (125, 65.45%) with unilateral (92.67%) affliction. Majority presented during the sixth (31.41%) or seventh (32.46%) decade of life. Most patients reported mild (37.07%) or moderate (27.32%) visual impairment, with vision < 20/200 being less common in HRVO (25.8%) and BRVO (17.2%) compared to CRVO (44.1%) (P < 0.00001). Glaucoma was diagnosed and treated in 49 (23.90%) eyes, which was much higher than CRVO (11.45%) and BRVO (5.04%) (P < 0.001), though neovascular glaucoma was much less than CRVO (2.9% vs. 9.2%) (P = 0.0037). On follow-up, HRVO eyes (12.2%) had lesser vision loss compared to CRVO eyes (13.7%) (this difference does not look very significant to me), though BRVO had the least (9.1%) vision loss. Conclusion: HRVO is a rare RVO, presenting more in males. It causes less-severe visual impairment compared to CRVO. Large majority of patients with HRVO do not have identifiable systemic risk factors other than age. Preexisting glaucoma was more associated with HRVO compared to other RVOs.
引用
收藏
页码:890 / 895
页数:6
相关论文
共 50 条
  • [31] Serous Retinal Detachment Associated With Retinal Vein Occlusion
    Tsujikawa, Akitaka
    Sakamoto, Atsushi
    Ota, Masafumi
    Kotera, Yuriko
    Oh, Hideyasu
    Miyamoto, Kazuaki
    Kita, Mihori
    Yoshimura, Nagahisa
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2010, 149 (02) : 291 - 301
  • [32] Cytokines and Pathogenesis of Central Retinal Vein Occlusion
    Noma, Hidetaka
    Yasuda, Kanako
    Shimura, Masahiko
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (11) : 1 - 16
  • [33] Vascular endothelial growth factor (VEGF) antagonists for central retinal vein occlusion: an update on clinical progress
    Stewart, Michael W.
    EXPERT REVIEW OF OPHTHALMOLOGY, 2024, 19 (01) : 67 - 76
  • [34] Branch Retinal Vein Occlusion: Classification and Treatment
    Parodi, Maurizio Battaglia
    Bandello, Francesco
    OPHTHALMOLOGICA, 2009, 223 (05) : 298 - 305
  • [35] Central retinal vein occlusion: the therapeutic options
    Madhusudhana, Krishnappa C.
    Newsom, Richard S. B.
    CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE, 2007, 42 (02): : 193 - 195
  • [36] Update and review of central retinal vein occlusion
    London, Nikolas J. S.
    Brown, Gary
    CURRENT OPINION IN OPHTHALMOLOGY, 2011, 22 (03) : 159 - 165
  • [37] Review: The Development of Risk Factors and Cytokines in Retinal Vein Occlusion
    Tang, Yi
    Cheng, Yan
    Wang, Shuo
    Wang, Yongjie
    Liu, Pengjia
    Wu, Hong
    FRONTIERS IN MEDICINE, 2022, 9
  • [38] Ranibizumab in retinal vein occlusion: treatment recommendations by an expert panel
    Gerding, Heinrich
    Mones, Jordi
    Tadayoni, Ramin
    Boscia, Francesco
    Pearce, Ian
    Priglinger, Siegfried
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2015, 99 (03) : 297 - 304
  • [39] Intravitreal Bevacizumab for Macular Edema Secondary to Retinal Vein Occlusion
    Parajuli, Anil
    Joshi, Purushottam
    Subedi, Prabha
    Pradhan, Chandni
    NEPALESE JOURNAL OF OPHTHALMOLOGY, 2020, 12 (02) : 281 - 289
  • [40] Relationship between retinal blood flow and cytokines in central retinal vein occlusion
    Noma, Hidetaka
    Yasuda, Kanako
    Mimura, Tatsuya
    Ofusa, Akemi
    Shimura, Masahiko
    BMC OPHTHALMOLOGY, 2020, 20 (01)